Health Canada Approves Blenrep (belantamab mafodotin) Combinations for Relapsed or Refractory Multiple Myeloma Read more about Health Canada Approves Blenrep (belantamab mafodotin) Combinations for Relapsed or Refractory Multiple MyelomaAdd new comment
European Commission Approves Darzalex Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma Read more about European Commission Approves Darzalex Subcutaneous Monotherapy for High-Risk Smoldering Multiple MyelomaAdd new comment
The International Myeloma Foundation Brings the Patient Voice and Science to FDA-ODAC Meeting; Advocates for BLENREP® (belantamab mafodotin) in Triplet Drug Combinations for the Treatment of Relapsed/Refractory Myeloma Read more about The International Myeloma Foundation Brings the Patient Voice and Science to FDA-ODAC Meeting; Advocates for BLENREP® (belantamab mafodotin) in Triplet Drug Combinations for the Treatment of Relapsed/Refractory Myeloma Add new comment
July 2025 – Myeloma News from the Journals Read more about July 2025 – Myeloma News from the JournalsAdd new comment
The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma Research Read more about The International Myeloma Foundation’s Brian D. Novis Research Grants: Celebrating 30 Years of Paving the Way for Transformative Breakthroughs in Myeloma ResearchAdd new comment
European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM) Read more about European Hematology Association (EHA) and the European Myeloma Network (EMN) Include Pepaxti in New Clinical Practice Guidelines for Relapsed/Refractory Multiple Myeloma (RRMM)Add new comment
FDA Grants Accelerated Approval to Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma Read more about FDA Grants Accelerated Approval to Lynozyfic™ (linvoseltamab-gcpt) for Relapsed/Refractory Multiple Myeloma Add new comment
The IMF Proudly Announces the Completion of EMA-CHMP”s Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trials Read more about The IMF Proudly Announces the Completion of EMA-CHMP”s Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical TrialsAdd new comment
FDA Eliminates REMS Program for Certain Autologous CAR T-cell Therapies Read more about FDA Eliminates REMS Program for Certain Autologous CAR T-cell TherapiesAdd new comment
FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel) Read more about FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel)Add new comment
